Join Free For Buyer|Sign In
Professional Online Trade Platform for API, Preparation and Pharmaceutical Machinery and
You are here:  Home >>  


Editors' Picks
  • Which are to Dominate the Chinese HCV Drug Market: A Review of DAAs in China
    So far, there are four HCV DAAs marketed in Mainland China, including the above two, BMS’ Asunaprevir soft capsule and Daclatasvir Dihydrochloride Tables combined therapy, and J & J’s Simeprevir.
  • Overview of NDA of FDA in Q3: Nearly Half of the 11 New Drugs Possessing “Blockbuster” Potential
    FDA approved 11 new drugs in total (see the attached table for the details) in 2017 Q3. Time is the most objective judge and good things will always stand its tests.

Top Stories

Raising the Dose and Raising the Cost: The Case of Pembrolizumab in Lung Cancer

After adjusting for inflation, the price per life-year gained of cancer drugs rose from $54 100 to $207 000 over the 20-year time period between ...
Follow Us
CPhI Online Trade Platform: Worldwide|English|中国站
Customer Service:  86-400 610 1188 (9: 00-18: 00, Mon-Fri)
About Us| Contact Us| Terms of Services| Privacy Policy| Intellectual Property Statement| Links | Site Map
Copyright 2006-20 Shanghai UBM Sinoexpo International Exhibition Co Ltd (All Rights Reserved). ICP 05034851-53